From Garage to Global Genomics Leader: Illumina's Rise in Under Two Decades

Illumina is a legend in the field of life sciences, being the game-changer of second-generation sequencing technology. Over the past 20 years, it has broken the Moore's Law that constrained industry development, pushing global life science research to an entirely new level.

Founded in 1998, this company's earliest core technology was based on a patent from Tufts University related to fiber optic etching and information processing. From a single patent to a small workshop with fewer than 10 people, and then to becoming a global leader, the establishment and development of Illumina would not have been possible without Larry Bock, John Stuelpnagel, David Walt, Mark Chee, and Jay Flatley.

Larry Bock is a legendary investor and serial entrepreneur in the life sciences field. He once worked at Genentech when it was still a startup and became a partner at CW Group. Unlike traditional investment logic, Larry Bock prefers to incubate from scratch. He spends a lot of time researching global leaders in the industry and then interviews many top scientists in the field to find suitable business partners and technical partners to build companies with.

In this model, Larry Bock incubated more than a dozen listed companies such as Neurocrine, Pharmacopeia, Argonaut, Caliper, ARIAD, Athena, Vertex, and Onyx within five years.

Larry Bock, Co-founder of Illumina, Image from Illumina's Commemorative Poster

The opportunity for Illumina arose because Larry Bock saw potential in the field of biosensing. However, his first choice was not David Walt, a professor at Tufts University who later became his technical partner.

Professor David Walt, Co-founder of Illumina

Initially, Larry Bock approached renowned Caltech chemists Nate Lewis and Bob Grubbs, hoping to develop sensors capable of identifying a wide range of materials based on their chip technology. However, Larry Bock's pitch failed to impress the two professors, who instead accepted funding from another investment firm to establish a company called Cyrano Sciences.

Despite feeling frustrated, Larry Bock did not give up on opportunities in this field. He began searching globally for similar technologies and the scientists who possessed them. After several years of exploration, he remembered one person—Professor David Walt from Tufts University.

Larry Bock and David Walt met five years ago. At that time, Larry Bock had considered investing in Professor David Walt's optical fiber technology. However, given that the technology was not mature enough at the time, the plan was abandoned. When Larry Bock visited again a few years later, the technology had advanced significantly.

In 1998, Larry Bock obtained the technology license from Tufts University. He and his assistant John Stuelpnagel co-founded a new company, with Professor David Walt serving as the company's consultant.

At the time of its establishment, the company's operations were mainly overseen by John Stuelpnagel. During his tenure as interim CEO, John Stuelpnagel, together with Larry Bock, helped build the company's initial core team, which included chief scientist Tony Czarnik and geneticist Mark Chee, who drove the company’s expansion into the field of genetics. While preparing the materials for the company’s founding, John Stuelpnagel also came up with a name that would later become widely recognized—Illumina.

John Stuelpnagel, Co-founder of Illumina

David Walt's technology can create uniformly distributed small holes at the end of optical fibers based on an etching process. The size of these holes is several orders of magnitude smaller than anything previously reported in the literature. When a suspension containing microparticles is applied to the etched fiber, each hole can hold one microparticle. If fluorescent dyes are attached to the microparticles, it enables the identification and location of each particle.

Larry Bock believed that this technology could be used to detect any target, but he had not identified a specific field at the time, until the arrival of Mark Chee.

Before joining Illumina (then known as Caliper Technologies), Mark Chee served as the Genetics Director at Affymetrix. A brief introduction to Affymetrix: although rarely mentioned today, the company was a leader in the gene chip technology boom of the 1980s and gained global recognition for its gene chip business.

This is also one of the reasons why Larry Bock and John Stuelpnagel approached Mark Chee. They believed that Affymetrix was the leader in the chip business, and Mark Chee, with his product research experience, was a perfect fit.

Mark Chee, Co-founder of Illumina

However, Mark Chee was not initially interested in their plan. Although he was not satisfied with his current job situation, he preferred to do his own thing. Therefore, Larry Bock and John Stuelpnage spent some time continuing to instill in Mark Chee the vision for this technology until his own intuition told him — this technology would be highly valuable in the field of genomics.

After joining, Mark Chee gradually developed a method for genetic analysis using labeled magnetic beads, steering the company towards the field of genomics.

Jay Flatley was the successor to John Stuelpnagel as the company's leader. John Stuelpnagel serving as the interim CEO was merely a temporary measure; according to their original plan, the company aimed to find a CEO with both courage and experience.

After completing the first round of major financing, Illumina recruited, through a headhunter, the CEO who would lead them through thick and thin for the next 20 years — Jay Flatley. Jay Flatley was the co-founder and CEO of Molecular Dynamics, an analytical instruments company. The year he joined Illumina, he had just successfully exited from Molecular Dynamics. In the nearly 20 years that followed, Jay Flatley led Illumina from an obscure startup to become the dominant force in the global sequencing field.

The addition of Jay Flatley also marks the completion of Illumina's core team construction. From conception to establishment, Illumina has been a results-oriented project led by investors, with the following characteristics in its formation process:

1. Bring together outstanding individuals in science, operations, and business;

2. Lock in the most visionary scientists, build companies around their technologies, find scientists who can solve problems and build applications, and appoint an experienced CEO;

3. Establish an advisory board, and scientists do not participate in business operations.

The establishment of the team is just the first step; the vast journey has only just begun.

Illumina initially did not engage in any sequencing instrument business. Larry Bock and John Stuelpnagel's original idea was to make Illumina a biochemical testing company, but it was Mark Chee’s background that steered the company towards the field of genomics.

In its early days, Illumina focused on the field of genetic analysis, with its main product being gene chips. It also offered some systems and services related to genotyping and gene expression arrays. After launching several products and services, Illumina gradually gained recognition in the industry. Not only did it sign a service agreement with GlaxoSmithKline, but its technology also became widely adopted by key laboratories and researchers worldwide.

They also acquired a company called CyVera to obtain a new technology, VeraCode, applicable for target validation and molecular assay development.

In 2006, a historic turning point occurred in the sequencing field. The company acquired Solexa, an experimental sequencing instrument company, for $600 million, gaining the sequencing-by-synthesis technology. As a result, Illumina, previously focused on genotyping and microarray technologies, officially entered the sequencing instrument market.

After the acquisition was completed, Illumina carried out a restructuring of its operating structure, leveraging the synergistic advantages of its sequencing and genotyping businesses. From consumables and analytical tools to sequencing instruments, Illumina achieved full coverage of the upstream market. During this period, they also continuously introduced products tailored to the needs of the research market, including whole-genome expression arrays, high-throughput DNA methylation cancer panels, and more.

In the sequencing business, Illumina digested and improved Solexa's technology and established a distribution network company. In 2007, Illumina announced its first profitable 12 months within five years, and the company was named the fastest-growing technology company by Forbes.

In its tenth year of development, Illumina broke two rules: one was the implicit agreement of not competing with customers; the other was the industry's inherent perception of the pace at which sequencing costs would decline.

Before 2012, Illumina never competed with its customers, but this situation changed after Illumina entered the clinical field.

In September 2012, Illumina acquired Blue Gnome, a British genetic variation sequencing service company. In January 2013, Illumina again spent $350 million to acquire Verinata Health. The news shocked the entire industry, as Verinata was a direct competitor of Illumina in the non-invasive prenatal testing field.

In July of the second year, Illumina made another move by acquiring Myraqa, a consulting firm focused on companion diagnostics and other IVDs, paving the way for the application of genomics technology in regulated markets and promoting standards used in clinical practice.

Although some people think that Illumina's move is creating enemies everywhere, the company actually has its own plans. First, the company sees the vast market in clinical services and wants to get a share. On the other hand, although entering the clinical field means they will be in competition with their customers, if the competition in the clinical market can drive the market for sequencers and actual consumables, then ultimately, Illumina itself will still benefit the most.

After this, Illumina changed its original clinical market sales strategy. They defined their sales targets as laboratories or other NIPT companies that wished to use the equipment, promoting device sales by popularizing sequencing technology.

Subsequently, with the launch of multiple precision oncology drugs, Illumina also signed a companion diagnostic product development agreement with Bristol-Myers Squibb.

At the same time, Illumina is also venturing into rare disease testing. Genomics has been attributed significant value and holds great importance in hereditary and rare diseases, including some rare conditions that cannot be diagnosed by traditional methods. Based on the specificity of mutations, different diseases will receive different treatments; drugs will also have a greater impact, and trials can achieve greater success.

Illumina maintains close collaborations with laboratories such as the Broad Institute, conducting rare disease research through methods like methylation and whole-genome sequencing. Meanwhile, the company has also initiated the "iHope" program to help families of children with undiagnosed rare diseases identify the causes.

However, by comparison, the breaking of the second rule is even more groundbreaking.

2014 was hailed as the first year of commercialization of sequencing technology. At that year's JP Morgan Conference, Illumina launched its latest generation of sequencers, the NextSeq series, and announced a reduction in sequencing costs from $100 million to $1,000. A global frenzy of commercial applications for genetic sequencing began. Companies, large and small, sprouted up like mushrooms after rain: non-invasive prenatal testing, tumor companion diagnostics, early cancer screening, consumer genomics, agricultural breeding... The second-generation sequencing technology displayed unprecedented vitality. The world’s top investors, entrepreneurs, and scientists all focused their attention here.

It is precisely because of its special contribution to the reduction in sequencing costs that Illumina, with its NextSeq series of sequencers, has defeated Roche and Thermo Fisher to become the dominant player in the sequencing market, with a market share reaching 80%. Subsequently, Illumina launched the NovaSeq series, making the sequencing cost at the level of hundreds of dollars once again a hot topic in the industry.

Brian Arthur, the founder of complexity science, pointed out in his book "The Nature of Technology" that qualitative changes in technology based on core fields will trigger transformations in commercial systems, reaching a new equilibrium through a series of new models. In the field of sequencing, cost changes following a super-Moore's Law have brought tremendous opportunities.

The decline in cost has once again led Illumina to see two more super markets: early cancer screening and consumer genomics.

In fact, not long after entering the sequencing market, Illumina made an initial foray into consumer genomics. Through the Understand Your Genome Project (UYG), the company promoted genetic consumption by offering deeper sequencing than products from 23andMe and earlier generations. For less than $3,000, users could discover which drugs they might be immune to or whether they carry genetic mutations that increase the risk of breast and ovarian cancer.

Among the two companies invested and established in 2016, Helix is the embodiment of Illumina's consumer genomics strategy. Illumina aims to further promote the integration of DNA into everyday life. The initial concept of this company introduced a new model for DNA informatics — an "app store." Unlike other companies that offer one product per test, Helix chooses to first provide consumers with a full-genome test at a low price, then gradually sell individual reports over time.

This company secured $100 million in financing right from the start. However, apart from the launch of its product in 2017, there has been little news from Helix.

By contrast, another company, GRAIL, has garnered more attention. Focused on the early detection of multiple cancer types, GRAIL has completed five rounds of financing since its establishment, accumulating over $2 billion in funding. After the Series B round, Illumina considered spinning off GRAIL to make this subsidiary one of its clients. However, after GRAIL repurchased its shares from Illumina, Illumina reacquired GRAIL for $8 billion.

The sequencing instrument, paired with chip business, means Illumina has a firm grasp on the industry's lifeline.

Of course, behind the success, there have been bitter moments. Over the past 20-plus years, Illumina has faced multiple fatal setbacks.

At the beginning of its establishment, the company's main business was gene chips, but at that time, there was already a leader in the industry, Affymetrix, where Mark Chee had previously worked.

In 2000, Illumina finally went public in a tight spot. Jay Flatley, with a medical background, raised 100 million US dollars during the peak period of genetic concept stocks. However, at this time, Affymetrix's revenue was 153 times that of Illumina.

After its IPO, Illumina's net income saw a significant decline, with losses exceeding $40 million in 2002, nearly double that of 2001. This pace caused shareholders to completely lose trust in Illumina, leading to a mass sell-off of its stock, causing the share price to plummet to as low as $1 at one point.

During this period, internal conflicts within the team also began to erupt. Jay Flatley fired Anthony Czarnik, a co-founder and chief scientist at the time.

"It was the lowest point of my career," Jay Flatley recalled.

In the following years, Illumina's development remained lukewarm until it acquired Solexa in 2006 and entered the genetic sequencing field. This was almost the key factor that determined Illumina’s success or failure. However, behind the favorable momentum of development, the seeds of yet another crisis for the company were sown.

At that time, there were three companies in the United States that manufactured second-generation sequencers: 454, Solexa, and ABI. The sequencing system based on pyrosequencing launched by 454 before 2005 pioneered the way for sequencing by synthesis and was also reported as a milestone event in Nature magazine. The year after Illumina acquired Solexa, Roche also brought 454 under its wing.

After acquiring Solex, Illumina's development has been advancing rapidly. Through numerous acquisitions, Illumina is determined to打通技术产业链and consolidate its dominant position in the field. This has drawn the attention of Roche.

In 2012, Roche proposed a cash acquisition of Illumina for $5.7 billion. Roche stated that they value the application prospects of the sequencing industry in future clinical diagnostics and drug research. If the acquisition of Illumina is successful, Roche's position in the life sciences and diagnostics market will be effectively enhanced.

Illumina considered this a hostile takeover. Bankers believed it was only a matter of time before Roche acquired Illumina, but CEO Jay Flatley and shareholders were infuriated. Jason Young, the third-largest shareholder, even stated: "We will not sell Illumina to Roche at any price."

As a result, the two parties engaged in intense negotiations. To block Roche, on January 26, 2012, Illumina announced that it would grant existing shareholders the right to purchase shares at half price. Shareholders who still held company stock after the market closed on February 6 would be incentivized through the distribution of one preferred share purchase right for each common share held. Additionally, investors were granted the right to purchase shares valued at $550 for $275. Calculated at $55 per share, this represented ten common shares.

This is what is known as a poison pill plan. In the end, Roche was forced to abandon its acquisition of Illumina, and Illumina's market value today far exceeds Roche's offer at that time.

Roche Began Gradually Closing 454 Life Sciences Business in 2013, Cutting About 100 Jobs. In a statement email, Roche said, "The 454 sequencer will be gradually phased out by mid-2016, and the 454 facility in Branford, Connecticut will also be closed as a result."

Reviewing the growth history of Illumina, we can see the incubation logic of some early American investment institutions, the strategies for the establishment and incubation of technology transfer companies, as well as the strategic transformation and comebacks of small companies, and the path of mergers and acquisitions from small companies to large ones. However, no giant enterprise has developed without challenges. The reason they have become dominant in a certain field is that they have risen from the ashes in every crisis, emerging stronger after each setback.

Similarly, after outcompeting 454 and ABI, Illumina will continue to face new challenges. The rise of Oxford Nanopore and MGI Tech has reignited a fierce competition in the sequencing instrument market. Even giants at the peak must remain vigilant, as they could be surpassed by emerging competitors. Therefore, from consumables to core technologies, and from applications to cutting-edge explorations, Illumina’s pursuit of self-breakthrough never stops.

Competition is eternal, and Illumina has not stopped.